

1. Record Nr.	UNINA9910484921203321
Titolo	Large and medium size vessel and single organ vasculitis // edited by Carlo Salvarani, Luigi Boiardi, Francesco Muratore
Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2021] ©2021
ISBN	3-030-67175-5
Descrizione fisica	1 online resource (274 pages)
Collana	Rare Diseases of the Immune System
Disciplina	616.13
Soggetti	Vasculitis Llibres electrònics
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Intro -- Preface -- Contents -- Part I: Giant Cell Arteritis -- 1: Classification Criteria -- References -- 2: Epidemiology and Genetics -- 2.1 Epidemiology -- 2.2 Genetics -- References -- 3: Pathogenesis -- 3.1 Introduction -- 3.2 Model of GCA Pathogenesis -- 3.3 Role of Infectious Agents -- 3.4 Genetics -- 3.5 Immune Effectors of Inflammation in Arteries -- 3.6 Arterial Remodeling -- 3.7 Epigenetics -- 3.8 MicroRNA -- 3.9 Deregulation of the Immune System in Peripheral Blood -- 3.10 Pathways Proven to be Involved in GCA Pathogenesis -- References -- 4: Clinical Manifestations, Differential Diagnosis, and Laboratory Markers -- 4.1 Clinical Manifestations of Giant Cell Arteritis -- 4.2 Differential Diagnosis of Giant Cell Arteritis -- 4.3 Laboratory Markers -- References -- 5: Histopathology and Imaging -- 5.1 Imaging -- 5.2 Temporal Artery Imaging -- 5.3 Large-Vessel Imaging -- References -- 6: Prognosis and Disease Activity -- 6.1 Risk for Complications and Comorbidities During Disease Course -- 6.2 Risk Factors and Biomarkers for Disease Activity in Giant Cell Arteritis -- 6.3 Additional Biomarkers for Assessment of Prognosis-Relevant Comorbidities -- References -- 7: Treatment and Management -- 7.1 General Aspects -- 7.2 Glucocorticoids as First-Line Treatment -- 7.3 Glucocorticoid(GC)-Sparing Agents -- 7.4 Treatment of Comorbidities/Adjuvant Therapies -- References -- Part II: Takayasu Arteritis -- 8: Classification Criteria,

Epidemiology and Genetics -- and Pathogenesis -- 8.1 Classification Criteria -- 8.2 Epidemiology and Genetics -- 8.2.1 Incidence and Prevalence -- 8.2.2 Sex -- 8.2.3 Age at Diagnosis -- 8.2.4 Major Histocompatibility Complex -- 8.2.5 Non-MHC -- 8.3 Pathogenesis -- References -- 9: Clinical Manifestations, Differential Diagnosis, and Laboratory Markers -- 9.1 Clinical Manifestations. 9.2 Physical Examination -- 9.3 Laboratory: Role of Acute-Phase Response -- 9.4 Differential Diagnosis -- 9.5 Large-Vessel Vasculitis Mimickers in the Differential Diagnosis of TAK -- References -- 10: Imaging -- 10.1 CTA -- 10.2 MRA -- 10.3 FDG-PET -- 10.4 Ultrasonography -- 10.5 Conclusion -- References -- 11: Prognosis and Disease Activity -- 11.1 Disease Activity Assessment -- 11.1.1 Physical Examination in Clinical Activity Assessment -- 11.1.2 Laboratory in Disease Activity Assessment -- 11.1.3 Imaging in Disease Activity Assessment -- 11.1.4 Outcome Measures in Disease Activity Assessment -- 11.2 Prognosis -- 11.2.1 Disease Course -- 11.2.2 Damage Assessment in TAK -- 11.2.3 Mortality -- 11.3 Conclusion -- References -- 12: Treatment -- 12.1 Non-biologic Disease-Modifying Agents -- 12.1.1 Methotrexate -- 12.1.2 Azathioprine -- 12.1.3 Leflunomide -- 12.1.4 Mycophenolate Mofetil -- 12.1.5 Cyclophosphamide -- 12.1.6 Other Non-biologic Disease-Modifying Agents -- 12.2 Biologic Disease-Modifying Agents -- 12.2.1 Tumor Necrosis Factor Inhibitors -- 12.2.2 Tocilizumab -- 12.2.3 Rituximab -- 12.2.4 Other Biologic Disease-Modifying Agents -- 12.3 Vascular Interventions and Surgical Therapy -- 12.4 Conclusion -- References -- Part III: Polyarteritis Nodosa -- 13: Cutaneous Polyarteritis Nodosa -- 13.1 Introduction -- 13.2 Epidemiology, Genetics, Pathogenesis -- 13.3 Clinical Manifestations and Laboratory Markers -- 13.3.1 Clinical Manifestations -- 13.3.2 Laboratory Markers -- 13.4 Histopathology -- 13.5 Diagnosis and Differential Diagnosis -- 13.6 Treatment -- 13.7 Prognosis and Disease Activity -- References -- 14: Systemic Polyarteritis Nodosa -- 14.1 Introduction -- 14.2 Epidemiology -- 14.3 Etiopathogenesis -- 14.4 Clinical Manifestations and Laboratory Markers -- 14.4.1 Clinical Manifestations. 14.4.2 Laboratory Markers -- 14.5 Histopathology -- 14.6 Diagnosis and Differential Diagnosis -- 14.7 Prognosis -- 14.8 Treatment -- References -- Part IV: Single Organ Vasculitis -- 15: Adult Primary Central Nervous System Vasculitis -- 15.1 Introduction -- 15.2 Diagnosis and Diagnostic Criteria -- 15.3 Histopathology -- 15.4 Clinical Manifestations and Laboratory Findings -- 15.5 PCNSV Subsets -- 15.6 Differential Diagnosis -- 15.7 Treatment -- 15.7.1 Mayo Clinic Cohort of Patients with Adult PCNSV -- 15.7.2 French Cohort of Patients with Primary Central Nervous System Vasculitis -- 15.7.3 Monitoring Disease Course -- References -- 16: Isolated Aortitis and Periaortitis -- 16.1 Introduction -- 16.2 Clinical Features and Diagnosis -- 16.2.1 Isolated Aortitis -- 16.2.2 Periaortitis -- 16.2.3 IgG4-Related Aortitis and Periaortitis -- 16.3 Treatment -- 16.4 Conclusions -- References -- 17: Isolated Gastrointestinal Vasculitis -- 17.1 Introduction -- 17.2 Epidemiology -- 17.3 Clinical Manifestations -- 17.4 Diagnosis -- 17.5 Differential Diagnosis -- 17.6 Management -- 17.7 Prognosis -- References -- 18: Cutaneous Vasculitis -- 18.1 Introduction -- 18.2 Nomenclature and Classification of Cutaneous Vasculitis -- 18.3 Clinical Spectrum of Cutaneous Vasculitis -- 18.4 Cutaneous Vasculitic Manifestations in Systemic Vasculitides with Predominant Organ Involvement Different from the Skin -- 18.4.1 Polyarteritis Nodosa -- 18.4.2 Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis --

18.4.2.1 MPA -- 18.4.2.2 GPA -- 18.4.2.3 EGPA -- 18.4.3 Immune Complex Small-Vessel Vasculitis -- 18.4.3.1 IgA Vasculitis (IgAV) -- 18.4.3.2 Cryoglobulinemic Vasculitis -- 18.4.3.3 Urticarial Vasculitis -- 18.5 Cutaneous Vasculitis Associated with Autoimmune Systemic Diseases -- 18.5.1 Rheumatoid Arthritis (RA). 18.5.2 Systemic Lupus Erythematosus (SLE) -- 18.5.3 Primary Sjogren Syndrome (PSS) -- 18.6 Cutaneous Single-Organ Vasculitis (SOV) -- 18.6.1 Erythema Elevatum et Diutinum (EED) -- 18.6.2 Nodular Vasculitis (Erythema Induratum of Bazin) -- 18.6.3 Hypergammaglobulinemic Macular Vasculitis (Hypergammaglobulinemic Purpura of Waldenström) -- 18.7 Diagnostic Approach in a Patient Presenting with Cutaneous Vasculitis -- 18.8 Treatment of Cutaneous Vasculitis -- References -- 19: Single-Organ Genitourinary Vasculitis -- 19.1 Introduction -- 19.2 Gynecologic Single-Organ Vasculitis -- 19.3 Male Genital Tract Single-Organ Vasculitis -- 19.3.1 Testicles, Epididymis, and Spermatic Cords -- 19.3.2 Prostate, Seminal Vesicles, and Penis -- 19.4 Urinary Tract Single-Organ Vasculitis -- 19.4.1 Ureters -- 19.4.2 Urinary Bladder -- 19.4.3 Urethra -- 19.5 Conclusions -- References -- Part V: Arterial and Venous Involvement in Behcet's Disease -- 20: Arterial and Venous Involvement in Behcet's Disease -- 20.1 Epidemiology -- 20.2 Pathology -- 20.3 Pathophysiology -- 20.4 Clinical Features and Prognosis of Venous Involvement -- 20.4.1 Deep Vein Thrombosis of Lower Extremities -- 20.4.2 Venous Wall Thickness in Behcet's Disease -- 20.4.3 Thrombosis of Superior and Inferior Vena Cava -- 20.4.4 Budd-Chiari Syndrome -- 20.4.5 Cerebral Sinus Thrombosis -- 20.5 Clinical Features and Prognosis of Arterial Involvement -- 20.5.1 Pulmonary Arterial Involvement -- 20.5.2 Peripheral Arterial Involvement -- 20.5.3 Cardiac Involvement -- 20.6 Imaging in Vascular Involvement of Behcet's Disease -- 20.7 Diagnosis -- 20.8 Treatment -- 20.8.1 Medical Treatment -- 20.9 Anticoagulation -- 20.10 Surgical Treatment -- 20.11 Conclusion -- References -- Correction to: Isolated Gastrointestinal Vasculitis. Correction to: C. Salvarani et al. (eds.), Large and Medium Size Vessel and Single Organ Vasculitis, Rare Diseases of the Immune System, https://doi.org/10.1007/978-3-030-67175-4_17 -- Index.
